Pfizer stops Phase 3 trial Of Lyrica (pregabalin) capsules CV in neuropathic pain associated with HIV neuropathy
4 May 2012 | By Pfizer
Pfizer has stopped a Phase 3 clinical trial of Lyrica in patients with neuropathic pain...
List view / Grid view
News
James Shannon named GlaxoSmithKline Chief Medical Officer
4 May 2012 | By GlaxoSmithKline
James Shannon has been named GSK’s Chief Medical Officer, effective 1 May...
Pfizer reports top-line results from Phase 3 trial of Lyrica (pregabalin) capsules CV in patients with inadequately treated painful diabetic peripheral neuropathy
4 May 2012 | By Pfizer
Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients...
Alan Schafer to head Population Genetics
3 May 2012 | By Alto Marketing
Population Genetics Technologies Ltd., has appointed Alan Schafer, PhD to the post of Chief Executive Officer...
Gerresheimer shows syringe systems at Korea Pack 2012
3 May 2012 | By Gerresheimer
Gerresheimer will be displaying its comprehensive range of prefillable syringe systems at Booth K701 of the Korea Pack...
Genzyme announces regulatory approvals of expanded Waterford, Ireland manufacturing plant
3 May 2012 | By Sanofi
FDA and the EMA approve 2nd operation for filling and finishing product...
Roche reports positive study of RoACTEMRA given by subcutaneous injection
3 May 2012 | By Roche
Roche announced that the SUMMACTA study met its primary endpoint...
Abbott announces collaboration with Syngene to open first nutrition R&D center in India
3 May 2012 | By Abbott
Abbott plans to establish its first nutrition R&D center with Syngene...
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
3 May 2012 | By GlaxoSmithKline
GlaxoSmithKline plc announces that Ms. Lynn Elsenhans and Ms. Jing Ulrich will join the Board...
Sandoz to acquire Fougera Pharmaceuticals
2 May 2012 | By Novartis
Definitive agreement to acquire Fougera Pharmaceuticals for USD 1.525 billion in an all-cash transaction...
Novo Nordisk A/S purchases B shares worth DKK 4.2 billion from Novo A/S
2 May 2012 | By Novo Nordisk
Novo Nordisk A/S has entered into an agreement to purchase 5,100,000 B shares...
New product launches on track and revenue continues to show growth, excluding Lexapro (US)
2 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S reports first quarter revenue of DKK 3,442 million...
Syrris offers global program of free training for chemists
2 May 2012 | By Syrris
Syrris is building on the success of its previous flow chemistry and automated process chemistry seminars...
Oxford BioTherapeutics appoints senior industry leader to head its new clinical development operations
2 May 2012 | By Citigate Dewe Rogerson
Dr Esteban Pombo-Villar appointed as COO of the OBT group...
Recent publicly-funded CATT trial highlights serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis
1 May 2012 | By Novartis
Results from two-year CATT...
